Pharmascience acquires securities of Bellus Health Inc.

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES AND NOT FOR DISSEMINATION IN THE UNITED STATES/

MONTREAL, May 25, 2012 /CNW Telbec/ - Pharmascience Inc. ("Pharmascience") announced today that, in connection with the entering into of a strategic partnership (the "Arrangement") with BELLUS Health Inc. ("BELLUS") effective May 25, 2012, it has acquired control over 104 units of BHI Limited Partnership (the "Units"), which Units are convertible into common shares of BELLUS (the "BELLUS Shares").

Immediately after completion of the Arrangement, the BELLUS Shares were consolidated on a 1:30 basis. Assuming the conversion in full of the Units, Pharmascience would acquire control over 6,350,638 BELLUS Shares representing approximately 10.4% of the outstanding BELLUS Shares on a fully diluted basis assuming the full conversion of all outstanding convertible securities of Bellus.

Pharmascience acquired the Units as a result of the Arrangement and not with a view to materially affecting control of BELLUS.

Caroline McNicoll at [phone]